Summit Therapeutics Inc. Contingent Liabilities Recognised As Of Acquisition Date
Summit Therapeutics Inc. (SMMT) had Contingent Liabilities Recognised As Of Acquisition Date of GBP 1.50 million as of 2018-04-30, per its 6-K filed 2018-06-05.
Discontinued › Notes
ifrs-full:ContingentLiabilitiesRecognisedAsOfAcquisitionDate · last filed 2018-06-05
- 2018-04-30: Contingent Liabilities Recognised As Of Acquisition Date 1.50M GBP.
- 2018-01-31: Contingent Liabilities Recognised As Of Acquisition Date 1.51M GBP.
| Period end | Contingent Liabilities Recognised As Of Acquisition Date |
|---|---|
| 2018-04-30 | 1.50M GBP 6-K · filed 2018-06-05 |
| 2018-01-31 | 1.51M GBP 6-K · filed 2018-06-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |